New Breast Cancer Patient Resource Is Available

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 11
Volume 5
Issue 11

WILMINGTON, Del-The Breast Cancer Patient Education Service, recently established by Zeneca Pharmaceuticals, allows breast cancer patients and their families to obtain patient education materials on tamoxifen (Nolvadex) with one phone call.

WILMINGTON, Del—The Breast Cancer Patient Education Service, recently established by Zeneca Pharmaceuticals, allows breast cancer patients and their families to obtain patient education materials on tamoxifen (Nolvadex) with one phone call.

The service provides the Progress for Life educational package, which includes written materials explaining breast cancer issues in easy-to-understand language and a video featuring experts on tamoxifen treatment, as well as useful toll-free numbers for other breast cancer information resources.

Patients can access the service by calling 1-800-34-LIFE-4 (1-800-345-4334), Monday through Friday, 8:15 AM until 4:30 PM Eastern Standard Time.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content